<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-933
Date of Submission: 2025-06-22

This report was submitted by a Nurse from Brooks-Adkins Medical Center concerning patient ANON-PX-9102. The subject is a 43-year-old female with a significant medical history including anxiety, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 393mg, initiated on 2025-05-20 for Hypercholesterolemia and discontinued on 2025-06-20.

On approximately 2025-06-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Anaphylaxis, Pruritus. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed amount and advised door. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed beyond and advised later. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Security fast gas hard material able player. Question employee professor finish. Suggest seem talk box southern summer community maintain.</data>
report_id: ADR-2025-933
report_date: '2025-06-22'
patient_details:
  patient_id: ANON-PX-9102
  gender: Female
  relevant_history:
  - anxiety
  - seasonal allergies
  age_at_reaction: 43
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 393mg
  route_of_administration: Topical
  start_date: '2025-05-20'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-06-20'
adverse_reactions:
- symptom_name: Diarrhea
  onset_date: '2025-06-19'
  severity: Moderate
  outcome: Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-06-19'
  severity: Moderate
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed amount and advised door.
- symptom_name: Pruritus
  onset_date: '2025-06-19'
  severity: Severe
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed beyond and advised later.
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 10
reporting_facility: Brooks-Adkins Medical Center
reporter_type: Nurse
notes: Security fast gas hard material able player. Question employee professor finish.
  Suggest seem talk box southern summer community maintain.
